Camphytolacton | 19893-77-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: Camphytolacton
• 英文别名: 2-Oxabicyclo[2.2.1]heptan-3-one, 1,7,7-trimethyl-；1,7,7-trimethyl-2-oxabicyclo[2.2.1]heptan-3-one
• CAS: 19893-77-7
• 化学式: C₉H₁₄O₂
• 分子量: 154.209
• InChiKey: SQRDEVDPDGSBGC-UHFFFAOYSA-N

物化性质

• 熔点：
  156-157 °C
• 沸点：
  226.5±8.0 °C(Predicted)
• 密度：
  1.056±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2932209090

反应信息

• 作为反应物：
  描述：

  Camphytolacton 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Tiemann; Kerschbaum, Chemische Berichte, 1900, vol. 33, p. 2938

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 Camphytolacton
  参考文献：
  名称：

  Blanc, Bulletin de la Societe Chimique de France, 1901, vol. <3> 25, p. 73

  摘要：

  DOI：

文献信息

• Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
  申请人：——

  公开号：US20040259915A1

  公开（公告）日：2004-12-23

  The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and/or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and/or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

  本发明涉及新颖的含杂原子四环衍生物、含有它们的药物组合物、它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的应用，以及它们的制备方法。本发明的化合物在治疗和/或预防与雌激素耗竭相关的疾病中具有用途，例如热潮红、阴道干燥、骨量减少和骨质疏松症；激素敏感性癌症以及乳腺、子宫内膜、宫颈和前列腺的增生；子宫内膜异位症、子宫肌瘤、骨关节炎，以及作为避孕剂，单独使用或与孕激素或孕激素拮抗剂联合使用。
• METHOD FOR MANUFACTURING ESTER
  申请人：Ishihara Kazuaki

  公开号：US20130217898A1

  公开（公告）日：2013-08-22

  The present invention relates to a method for manufacturing an ester from a ketone or an aldehyde, which is a reactive substrate, by a Baeyer-Villiger oxidation reaction using hydrogen peroxide, and in this method, as a catalyst, M(BAr 4 ) n , which is a metal borate, is used (M represents an alkali metal or an alkaline earth metal; Ar represents an aryl; and n is the same number as the valence of M). For example, when cyclohexanone was used as the reactive substrate, and Sr[B(3,5-CF 3 C 6 H 3 ) 4 ] 2 was used as the catalyst, ε-caprolactone was obtained at an isolated yield of 82%.

  本发明涉及一种从酮或醛（作为反应底物）制造酯的方法，该方法通过使用过氧化氢进行巴耶-维利格氧化反应，在该方法中，作为催化剂使用了M(BAr4)n，该催化剂是一种金属硼酸盐（M代表碱金属或碱土金属；Ar代表芳基；n与M的化合价相同）。例如，当环己酮作为反应底物，Sr[B(3,5-CF3C6H3)4]2作为催化剂时，得到了ε-己内酯，其分离收率为82%。
• Latent acids and their use
  申请人：Yamato Hitoshi

  公开号：US20110217654A1

  公开（公告）日：2011-09-08

  The invention pertains to a compound generating an acid of the formula I or II, for instance corresponding sulfonium and iodonium salts, as well as corresponding sulfonyloximes wherein X is CH 2 or CO; Y is O, NR 4 , S, O(CO), O(CO)O, O(CO)NR 4 , OSO 2 , O(CS), or O(CS)NR 4 ; R 1 is for example C 1 -C 18 alkyl, C 1 -C 10 haloalkyl, C 2 -C 12 alkenyl, C 4 -C 30 cycloalkenyl, phenyl-C 1 -C 3 -alkyl, C 3 -C 30 cycloalkyl, C 3 -C 30 cycloalkyl-C 1 -C 18 alkyl, interrupted C 2 -C 18 alkyl, interrupted C 3 -C 30 cycloalkyl, interrupted C 3 -C 30 cycloalkyl-C 1 -C 18 alkyl, interrupted C 4 -C 30 cycloalkenyl, phenyl, naphthyl, anthracyl, phenanthryl, biphenylyl, fluorenyl or heteroaryl, all unsubstituted or are substituted; or R 1 is NR 12 R 13 ; R 2 and R 3 are for example C 3 -C 30 cycloalkylene, C 3 -C 30 cycloalkyl-C 1 -C 18 alkylene, C 1 -C 18 alkylene, C 1 -C 10 haloalkylene, C 2 -C 12 alkenylene, C 4 -C 30 cycloalkenylene, phenylene, naphthylene, anthracylene, phenanthrylene, biphenylene or heteroarylene; all unsubstituted or substituted; R 4 is for example C 3 -C 30 cycloalkyl, C 3 -C 30 cycloalkyl-C 1 -C 18 alkyl, C 1 -C 18 alkyl, C 1 -C 10 haloalkyl, C 2 -C 12 alkenyl, C 4 -C 30 cycloalkenyl, phenyl-C 1 -C 3 -alkyl; R 12 and R 13 are for example C 3 -C 30 cycloalkyl, C 3 -C 30 cycloalkyl-C 1 -C 18 alkyl, C 1 -C 18 alkyl, C 1 -C 10 haloalkyl, C 2 -C 12 alkenyl, C 4 -C 30 cycloalkenyl, phenyl-C 1 -C 3 -alkyl, Ar, (CO)R 15 , (CO)OR 15 or SO 2 R 15 ; and Ar is phenyl, biphenylyl, fluorenyl, naphthyl, anthracyl, phenanthryl or heteroaryl, all unsubstituted or substituted.

  本发明涉及一种生成公式I或II的酸的化合物，例如对应的磺鎓盐和碘鎓盐，以及对应的磺酰氧肟，其中X为CH2或CO；Y为O、NR4、S、O（CO）、O（CO）O、O（CO）NR4、OSO2、O（CS）或O（CS）NR4；R1例如为C1-C18烷基、C1-C10卤代烷基、C2-C12烯基、C4-C30环烯基、苯基-C1-C3-烷基、C3-C30环烷基、C3-C30环烷基-C1-C18烷基、中断的C2-C18烷基、中断的C3-C30环烷基、中断的C3-C30环烷基-C1-C18烷基、中断的C4-C30环烯基、苯基、萘基、蒽基、菲基、苯并二氢呋喃基或杂环基，全部未取代或被取代；或R1为NR12R13；R2和R3例如为C3-C30环烷基、C3-C30环烷基-C1-C18烷基、C1-C18烷基、C1-C10卤代烷基、C2-C12烯基、C4-C30环烯基、苯基、萘基、蒽基、菲基、苯并二氢呋喃基或杂环基，全部未取代或被取代；R4例如为C3-C30环烷基、C3-C30环烷基-C1-C18烷基、C1-C18烷基、C1-C10卤代烷基、C2-C12烯基、C4-C30环烯基、苯基-C1-C3-烷基；R12和R13例如为C3-C30环烷基、C3-C30环烷基-C1-C18烷基、C1-C18烷基、C1-C10卤代烷基、C2-C12烯基、C4-C30环烯基、苯基-C1-C3-烷基、Ar、（CO）R15、（CO）OR15或SO2R15；Ar为苯基、苯并二氢呋喃基、菲基、萘基、蒽基、苯并蒽基或杂环基，全部未取代或被取代。
• Novel spiro-benzo[c]chromene derivatives useful as modulators of the estrogen receptors
  申请人：Zhang Xuqing

  公开号：US20060020018A1

  公开（公告）日：2006-01-26

  The present invention is directed to novel spiro-benzo[C]chromene derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

  本发明涉及新型螺-苯并[C]色烯衍生物、包含它们的制药组合物以及它们在治疗由一个或多个雌激素受体介导的疾病中的应用。该发明的化合物在治疗与雌激素消耗相关的疾病中如潮热、阴道干燥、骨质疏松症和骨质疏松症；激素敏感性癌症和乳腺、子宫内膜、宫颈和前列腺的增生；子宫内膜异位症、子宫肌瘤、骨关节炎以及作为避孕剂单独或与孕激素或孕激素拮抗剂联合使用方面是有用的。
• [EN] TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS<br/>[FR] HETERO-COMPOSES TETRACYCLIQUES UTILISABLES COMME MODULATEURS DU RECEPTEUR DES OESTROGENES
  申请人：ORTHO MCNEIL PHARM INC

  公开号：WO2003053977A1

  公开（公告）日：2003-07-03

  The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them, their use in the treatment and / or prevention of disorders mediated by one or more estrogen receptors and processes for their preparation. The compounds of the invention are useful in the treatment and / or prevention of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

  本发明涉及新型含杂原子的四环衍生物、含有它们的药物组合物、它们在治疗和/或预防由一个或多个雌激素受体介导的疾病中的使用以及它们的制备过程。该发明的化合物在治疗和/或预防与雌激素缺乏有关的疾病方面具有用处，例如潮热、阴道干燥、骨质疏松症和骨质疏松症；激素敏感性癌症和乳腺、子宫内膜、子宫颈和前列腺的增生；子宫内膜异位症、子宫肌瘤、骨关节炎以及作为避孕药物，单独使用或与孕激素或孕激素拮抗剂组合使用。